G2GBIO, INC.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2017-03-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.g2gbio.com
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
Phase 1
Recruiting
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- G2GBio, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06127368
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults
Phase 1
Completed
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- G2GBio, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06095973
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- G2GBio, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05525780
- Locations
- 🇨🇦
Syneos Health, Québec, Canada
News
No news found